Aytu BioPharma Rebounds as Depression Drug Prescriptions Surpass Expectations
Englewood, Tuesday, 22 September 2026.
Aytu BioPharma reported a 6.4% fourth-quarter revenue increase to $16.1 million, fueled by its depression treatment EXXUA, which saw total quarterly prescriptions skyrocket by 138%.
Quarterly Revenue and EXXUA Growth
Aytu BioPharma (NASDAQ: AYTU) released fiscal 2026 fourth-quarter results on September 22, 2026, revealing a 6.4% year-over-year increase in net revenue to $16.1 million [1]. This performance exceeded the consensus revenue estimate of $12.28 million anticipated by analysts prior to the announcement [2]. The company reported an Adjusted EBITDA of $0.5 million for the quarter, marking a shift towards profitability metrics compared to the previous year [1].
The growth was primarily driven by the commercial rollout of EXXUA, a treatment for major depressive disorder, which contributed $3.9 million in net revenue during the fourth quarter [1]. Total prescriptions for EXXUA reached 3,323 in the quarter, representing a significant increase from the 1,398 prescriptions recorded in the third quarter of fiscal 2026 [1]. This surge reflects a quarter-over-quarter growth rate calculated as 137.697 [1].
Commercial Dynamics and Legacy Portfolio
While EXXUA showed momentum, the legacy ADHD portfolio revenue decreased to $10.4 million in the fourth quarter of fiscal 2026, down from $13.1 million in the same period of 2025 [1]. This decline is attributed to reduced promotion and generic competition affecting products like Adzenys [1]. Despite this, the company maintained a cash balance of $26.3 million as of June 30, 2026, providing liquidity for ongoing operations [1].
Market analysts have noted significant volatility surrounding the company, with a ten-quarter average post-earnings stock move of 16.3% [3]. Valuation metrics present a complex picture, with some indicators suggesting the stock may be overvalued relative to its financial strength [4]. The company reported a trailing twelve months earnings per share of -4.58, highlighting the challenge of achieving consistent profitability [4].
Future Outlook and Analyst Projections
Industry analysts project a path to breakeven by 2028, requiring substantial annual growth rates [3]. The company aims to drive sustained growth and achieve consistent positive Adjusted EBITDA levels as fiscal 2027 progresses [1]. Investors are closely watching whether revenue holds above the recent run rate to validate the commercial strategy [3]. For the full fiscal year 2026, net revenue was $57.6 million, compared to $66.4 million in 2025, reflecting the transition phase of the business [1].